What one share of Matinas Biopharma Holdings holds
Matinas Biopharma Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.19 |
|---|---|
| Cash and investments | $0.12 |
| Book value | $0.28 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2013 | — | −$9.77 | $0.25 | −$8.11 | — | $16.37 |
| 2014 | $0.00 | −$15.93 | $0.45 | −$12.86 | — | $3.45 |
| 2015 | $0.19 | −$8.87 | $0.07 | −$7.66 | — | $5.31 |
| 2016 | — | −$10.40 | $0.00 | −$5.31 | — | $0.91 |
| 2017 | $0.08 | −$18.15 | $0.52 | −$6.85 | — | $5.72 |
| 2018 | $0.06 | −$7.64 | $0.27 | −$5.53 | — | $7.12 |
| 2019 | $0.03 | −$6.50 | $0.14 | −$4.99 | — | $8.91 |
| 2020 | $0.04 | −$5.90 | $0.00 | −$4.41 | — | $14.98 |
| 2021 | $0.01 | −$5.63 | $0.06 | −$3.68 | — | $12.14 |
| 2022 | $0.74 | −$5.00 | $0.21 | −$4.62 | — | $8.43 |
| 2023 | $0.25 | −$5.28 | $0.05 | −$3.57 | — | $4.43 |
| 2024 | — | −$4.98 | — | — | — | $1.49 |
| 2025 | — | −$2.00 | — | — | — | $0.75 |
Common questions about Matinas Biopharma Holdings
How much does one share of Matinas Biopharma Holdings earn?
Over the last 12 months, Matinas Biopharma Holdings lost $1.19 for each share.
Does Matinas Biopharma Holdings pay a dividend?
Matinas Biopharma Holdings didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Matinas Biopharma Holdings’s book value per share?
Matinas Biopharma Holdings’s book value is $0.28 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Matinas Biopharma Holdings have?
Each share of Matinas Biopharma Holdings has $0.12 of cash and investments, as of June 30, 2026.
Has Matinas Biopharma Holdings bought back shares?
Matinas Biopharma Holdings’s share count rose about 1340% from 2013 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.